Taken together, our findings suggest that some vicarious mechanisms, only partly relying on the activation of the A-NHEJ pathway, make the XRCC4 protein remarkably dispensable in humans, at least to warrant immunologic proficiency and anti-cancer surveillance. Here, XRCC4 is linked to cancer.